Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Draft Guidance: Rejects Keytruda In Head & Neck Cancer, Xospata In AML

But Positive On Lynparza And Ibrance In Certain Settings

Executive Summary

A series of decisions on anticancer drugs from the UK’s NICE will act as a reminder to drug developers excited by potential breakthroughs that health technology assessment has become an exacting filter for new medicines to pass through.

You may also be interested in...



NICE Rejects Tecentriq For Small-Cell Lung Cancer In England

Roche’s Tecentriq has been rejected by health technology assessment body NICE for use in small-cell lung cancer on the National Health Service. The move follows an earlier knockback for the drug in PD L1-positive triple-negative breast cancer.

Daiichi Sankyo Plays Long Game With Quizartinib Outside Japan

Japanese company Daiichi Sankyo has its eye on first-line FLT3-ITD AML indication after rejection of relapsed/refractory plans in EU and US.

Ibrance Joins Rival CDK4/6 Inhibitors In English Cancer Drugs Fund

Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141474

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel